Sanofi

Sanofi

Global pharma company; vaccines and R&D

Cyber Resilience and Business Continuity Intern

InternshipPosted on 9/24/2026Deadline 12/30/26
No salary listed
Bachelor's
Vitry-sur-Seine, France
In Person

About the job

Requirements
  • A Bac +4 or Bac +5 qualification in general engineering is required.
  • Intermediate English is required.
  • Strong rigor, organizational skills, and analytical thinking are required.
  • Proficiency in the Microsoft Office suite is required.
Responsibilities
  • Participate in validating degraded operating modes for critical processes in key areas such as production, utilities, supply chain, and quality control.
  • Help design realistic test scenarios and facilitate sessions with operational teams.
  • Contribute to training teams on validated degraded operating modes and creating practical training materials.
  • Participate in crisis-management training for site teams.
  • Help update business continuity plan documentation based on tests and field feedback.
  • Support schedule tracking and report on progress.
  • Contribute to continuous improvement of the business continuity process.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi completed Vicebio on December 4, 2025, adding RSV-HMPV vaccine technology.
  • Sanofi completed Dynavax on February 10, 2026, expanding hepatitis B and shingles assets.
  • FDA approved wearable Sarclisa on July 2026, improving multiple myeloma convenience.

What critics are saying

  • Dupixent loses patent exclusivity in 2031, exposing Sanofi’s cash engine.
  • EU regulators opened a June 26, 2026 antitrust probe over Efluelda marketing.
  • Sanofi sued Pfizer and Moderna on July 15, 2026 over COVID-shot patents.

What makes Sanofi unique

  • Dupixent and partner Regeneron still anchor Sanofi’s immunology franchise in 2026.
  • Vicebio’s Molecular Clamp and Dynavax deepen Sanofi’s respiratory and adult vaccine platform.
  • Frankfurt insulin manufacturing, backed by Germany’s 2026 subsidy, protects European supply security.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Electra Therapeutics
Sep 11th, 2026
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...